Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor β agonists via the phosphatidyl-inositol-3 kinase-Akt pathway

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 2, 2010, Pages 554-561

  Jiménez, Rosario ^a   Sánchez, Manuel ^a   Zarzuelo, María José ^a   Romero, Miguel ^a   Quintela, Ana María ^a   López Sepúlveda, Rocío ^a   Galindo, Pilar ^a   Gómez Guzmán, Manuel ^a   Haro, Jose Manuel ^c   Zarzuelo, Antonio ^a,b   Pérez Vizcaíno, Francisco ^d   Duarte, Juan ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Clinic Hospital of Granada   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 CHLORO 5 NITROBENZANILIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENYLEPHRINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VASODILATOR AGENT;

ANIMAL TISSUE; ARTICLE; ENDOTHELIUM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; UMBILICAL VEIN; VASCULAR RING; VASODILATATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANILIDES; ANIMALS; AORTA; CHROMONES; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; MALE; MORPHOLINES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHENOXYACETATES; PHOSPHORYLATION; PPAR-BETA; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SULFONES; THIAZOLES; THIOPHENES; UMBILICAL VEINS; VASODILATION;

EID: 76749129634     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.159806     Document Type: Article

References (43)

1. Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, Bishop-Bailey D, Warner TD, and Mitchell JA (2006) Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J 20:326-328.
2. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, and Komuro I (2002) Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105:1240-1246.
3. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, and Evans RM (2002) Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A 99:303-308.
4. Barish GD, Narkar VA, and Evans RM (2006) PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116:590-597.
5. Benkirane K, Amiri F, Diep QN, El Mabrouk M, and Schiffrin EL (2006) PPARgamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 290:H390-H397.
6. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, et al. (1999) Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem 274:6718-6725.
7. Burgermeister E and Seger R (2007) MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle 6:1539-1548.
8. Chen F, Wang M, O'Connor JP, He M, Tripathi T, and Harrison LE (2003) Phosphorylation of PPARgamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappabeta. J Cell Biochem 90:732-744.
9. Cheskis BJ, Greger JG, Nagpal S, and Freedman LP (2007) Signaling by estrogens. J Cell Physiol 213:610-617.
10. Cimini A, Benedetti E, Cristiano L, Sebastiani P, D'Amico MA, D'Angelo B, and Di Loreto S (2005) Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 130:325-337.
11. Di-Poï N, Tan NS, Michalik L, Wahli W, and Desvergne B (2002) Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 10:721-733.
12. Han JK, Lee HS, Yang HM, Hur J, Jun SI, Kim JY, Cho CH, Koh GY, Peters JM, Park KW, et al. (2008) Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. Circulation 118:1021-1033.
13. Hartell NA, Archer HE, and Bailey CJ (2005) Insulin-stimulated endothelial nitric oxide release is calcium independent and mediated via protein kinase B. Biochem Pharmacol 69:781-790.
14. Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, Diep QN, and Schiffrin EL (2003) Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 42:737-743.
15. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
16. Jiang B, Liang P, Zhang B, Song J, Huang X, and Xiao X (2009) Role of PPAR-beta in hydrogen peroxide-induced apoptosis in human umbilical vein endothelial cells. Atherosclerosis 204:353-358.
17. Jiménez R, López-Sepúlveda R, Kadmiri M, Romero M, Vera R, Sánchez M, Vargas F, O'Valle F, Zarzuelo A, Dueñas M, et al. (2007) Polyphenols restore endothelial function in DOCA-salt hypertension: role of endothelin-1 and NADPH oxidase. Free Radic Biol Med 43:462-473.
18. Jimenez R, Sanchez M, Zarzuelo MJ, Romero M, Lopez-Sepulveda M, Perez-Vizcaino F, and Duarte J (2007) Endothelium-dependent vasodilator effects of the PPAR β/δ agonist L-165041 in rat isolated aorta. Winter Meeting Brighton 2007; 2007 Dec 17-20; Brighton, UK.
19. Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AG, Pettersson S, and Conway S (2004) Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 5:104-112.
20. Khan O, Riazi S, Hu X, Song J, Wade JB, and Ecelbarger CA (2005) Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone. Am J Physiol Renal Physiol 289: F442-F450.
21. Kim DJ, Bility MT, Billin AN, Willson TM, Gonzalez FJ, and Peters JM (2006) PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Differ 13:53-60.
22. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, and Evans RM (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 91:7355-7359.
23. Kota BP, Huang TH, and Roufogalis BD (2005) An overview on biological mechanisms of PPARs. Pharmacol Res 51:85-94.
24. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, and Curtiss LK (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302:453-457.
25. Lee KS, Park JH, Lee S, Lim HJ, Jang Y, and Park HY (2006) Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity. Biochem Biophys Res Commun 346:83-88.
26. Leikert JF, Räthel TR, Müller C, Vollmar AM, and Dirsch VM (2001) Reliable in vitro measurement of nitric oxide released from endothelial cells using low concentrations of the fluorescent probe 4,5-diaminofluorescein. FEBS Lett 506:131-134.
27. Lim HJ, Lee S, Park JH, Lee KS, Choi HE, Chung KS, Lee HH, and Park HY (2009) PPARδ agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle. Atherosclerosis 202:446-454.
28. Moraes LA, Swales KE, Wray JA, Damazo A, Gibbins JM, Warner TD, and Bishop-Bailey D (2007) Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood 109:3741-3744.
29. Nagao T and Vanhoutte PM (1992) Characterization of endothelium-dependent relaxations resistant to nitro-L-arginine in the porcine coronary artery. Br J Pharmacol 107:1102-1107.
30. Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, and Bishop-Bailey D (2007) Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 27:63-69.
31. Piqueras L, Sanz MJ, Perretti M, Morcillo E, Norling L, Mitchell JA, Li Y, and Bishop-Bailey D (2009) Activation of PPARbeta/delta inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. J Leukoc Biol 86:115-122.
32. Risérus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, et al. (2008) Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57:332-339.
33. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, and Diep QN (2003) Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension 42:664-668.
34. Sheng L, Ye P, Liu YX, Han CG, and Zhang ZY (2008) Peroxisome proliferator-activated receptor beta/delta activation improves angiotensin II-induced cardiac hypertrophy in vitro. Clin Exp Hypertens 30:109-119.
35. Stahn C and Buttgereit F (2008) Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 4:525-533.
36. Stuehr DJ (1997) Structure-function aspects in the nitric oxide synthases. Annu Rev Pharmacol Toxicol 37:339-359.
37. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, et al. (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta) - synthesis and biological activity. Bioorg Med Chem Lett 13:1517-1521.
38. Takata Y, Liu J, Yin F, Collins AR, Lyon CJ, Lee CH, Atkins AR, Downes M, Barish GD, Evans RM, et al. (2008) PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci U S A 105: 4277-4282.
39. Vanhoutte PM, Rubanyi GM, Miller VM, and Houston DS (1986) Modulation of vascular smooth muscle contraction by the endothelium. Annu Rev Physiol 48: 307-320.
40. Vargas FF, Caviedes PF, and Grant DS (1994) Electrophysiological characteristics of cultured human umbilical vein endothelial cells. Microvasc Res 47:153-165.
41. Vosper H, Patel L, Graham TL, Khoudoli GA, Hill A, Macphee CH, Pinto I, Smith SA, Suckling KE, Wolf CR, et al. (2001) The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem 276: 44258-44265.
42. Walker JM (1994) The bicinchoninic acid (BCA) assay for protein quantitation. Methods Mol Biol 32:5-8.
43. Willson TM, Brown PJ, Sternbach DD, and Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550.